Roche becomes founding partner of biotech accelerator

By The Science Advisory Board staff writers

May 15, 2020 -- Roche has become a founding partner in the second phase of development of BaseLaunch, a Basel, Switzerland-based incubator and accelerator that helps scientists and entrepreneurs launch biotech companies.

Roche previously supported BaseLaunch from 2017 to 2019 during the company's first phase. Now in BaseLaunch's second phase of development, Roche is the first partner to be announced. More partners will be named in the coming months.

This second phase for BaseLaunch will do the following:

  • Increase the funding per venture to a maximum of $500,000 U.S. versus $250,000 U.S. previously
  • Establish the company as an "evergreen" permanent initiative
  • Accept applications year-round rather than once a year

During BaseLaunch's first phase, it supported nine early therapeutic ventures that raised a total of more than $100 million U.S. in equity capital from U.S. and European venture funds. Recently, the company added another four ventures to its portfolio.

Applications are open until June 22, 2020.

Arrakis Therapeutics partners with Roche
Biopharmaceutical firm Arrakis Therapeutics has inked a license agreement with Roche to collaborate on research of Roche's RNA-targeted small-molecule...
Real-Time PCR: A Mature Technology that is Still Evolving
Though a mature technology for many years, real-time PCR has still seen growth and advancements in both application as well as throughput efficiency over...
Oncologists Embrace the Liquid Biopsy for Precision Cancer Treatment
Here at The Science Advisory Board we aim to keep ahead of the curve with the latest breakthroughs in the life sciences field. An exciting advancement...
CRISPR - A New Era in Genome Editing
A major buzzword in the science world recently has been CRISPR: short for Clustered Regularly Interspaced Short Palindromic Repeats. This is a simple,...
Rise of Genomics Spurs Innovation in Instruments & Techniques
The global advance of health care increasingly depends on the study of genetics and the human genome. From determining the genetic composition of a tumor...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter